It is reported that AKT phosphorylation is reduced in the striatum of patients with PD, suggesting that its inactivation has an important role in PD [56]; being so, it is a substantial therapeutic target for treating neurodegenerative diseases, beyond other pathologies [57]. Here, AKT1 is linked to Parkinson disease.